Development of differentiation modulators and targeted agents for treating neuroblastoma

  • Eur J Med Chem. 2020 Dec 1:207:112818. doi: 10.1016/j.ejmech.2020.112818.
Zegao Jin  1 ,  Yang Lu  1 ,  Yizhe Wu  1 ,  Jinxin Che  2 ,  Xiaowu Dong  3
Affiliations
  • 1. Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China.
  • 2. Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China. Electronic address: [email protected].
  • 3. Hangzhou Institute of Innovative Medicine, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, 310058, PR China; Innovation Institute for Artificial Intelligence in Medicine, Zhejiang University, Hangzhou, 310058, PR China; Cancer Center of Zhejiang University, Hangzhou, 310058, PR China. Electronic address: [email protected].
PMID: 32937281 DOI: 10.1016/j.ejmech.2020.112818
Abstract

Neuroblastoma (NB) is one of the most common pediatric malignancies. Easy metastasis, poor prognosis, and a high degree of heterogeneity of NB hinder its successful treatment. Several different therapeutic strategies have been developed to overcome these problems, including differentiation and targeted therapy. In this review, we summarize the recent development of differentiation modulators and targeted agents for treating NB. Several promising targets of NB were also discussed.

Keywords
Differentiation therapy; Neuroblastoma; Targeted therapy.